OctaplasLG®

DRUG4 trials

Sponsors

Rigshospitalet, Denmark, Octapharma, University Hospital, Strasbourg, France

Conditions

Aortic Aneurysm, ThoracicCoagulopathyDisseminated Intravascular CoagulationEndothelial DysfunctionSeptic ShockThrombotic Thrombocytopenic Purpura

Phase 4

Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28)

CompletedNCT02253082

Rigshospitalet, DenmarkAortic Aneurysm, Thoracic, Endothelial Dysfunction

Start: 2014-11-30End: 2016-12-31Updated: 2016-12-20

Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial. VIPER-Sepsis (EudraCT no. 2016-000707-81)

TerminatedNCT02875236

Rigshospitalet, DenmarkSeptic Shock

Start: 2016-09-01End: 2016-11-08Updated: 2018-01-09

Unknown Phase

Observational Study of the Use of octaplasLG®.

CompletedNCT03369314

OctapharmaThrombotic Thrombocytopenic Purpura

Start: 2018-03-02End: 2021-01-14Updated: 2021-03-19

Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study

CompletedNCT04580563

University Hospital, Strasbourg, FranceCoagulopathy, Disseminated Intravascular Coagulation, Septic Shock

Start: 2020-10-22End: 2023-01-03Updated: 2026-03-16